Source comparison
Kisspeptin Safety: Route, Dose, and Frequency Comparison
IV Bolus (Single Dose) 0.01–3.2 nmol/kg Transient tachycardia (10–20 bpm increase), flushing 0% across all trials 30–60 minutes Fastest LH response, well-tolerated, ideal for research protocols assessing acute gonadotropin response Subcutaneous Injection (Sing
This comparison does not assign a generated winner or score.
- IV Bolus (Single Dose)
- 0.01–3.2 nmol/kg
- Transient tachycardia (10–20 bpm increase), flushing
- 0% across all trials
- 30–60 minutes
- Fastest LH response, well-tolerated, ideal for research protocols assessing acute gonadotropin response
- Subcutaneous Injection (Single Dose)
- 6.4–12.8 nmol/kg
- Mild injection-site erythema (15% incidence), transient tachycardia
- 60–90 minutes
- Slower onset than IV, practical for outpatient use, no systemic toxicity
- Continuous Subcutaneous Infusion
- 1–4 nmol/kg/hour for 10–24 hours
- Infusion-site tenderness, transient HR elevation during active infusion
- Sustained elevation over infusion duration
- Mimics pulsatile GnRH secretion most closely, used in IVF trigger protocols, no desensitisation observed
- Repeated Daily Dosing (Subcutaneous)
- 6.4 nmol/kg daily for 14–28 days
- Injection-site reactions (cumulative incidence ~20%), no systemic accumulation
- Stable LH/FSH elevation by day 3–5
- No tachyphylaxis, no receptor downregulation, hormone levels remain responsive throughout treatment window
- The table above reflects aggregated data from trials published between 2010 and 2024 in peer-reviewed endocrinology journals. The key insight: kisspeptin's safety profile holds across administration methods. The peptide does not accumulate toxically, does not produce withdrawal effects upon cessation, and does not cause receptor desensitisation even with daily dosing for a month.
- One critical clarification: all trials used research-grade kisspeptin synthesised under GMP conditions with verified amino-acid sequencing. Compounded or non-pharmaceutical-grade preparations have not been formally assessed for safety. Purity, sterility, and peptide integrity matter enormously for injectable biologics.